Company / Accounts Receivable
LENZ Therapeutics, Inc. Accounts Receivable History
FY2025-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$329.0K
FY2025
5-year range
$329.0K / $329.0K
FY2025-FY2025
Trend
-
vs FY2024
Sector context
#111 of 113
Health Care
What the data says
Among 113 Health Care companies, LENZ Therapeutics, Inc. is in the bottom 2% for accounts receivable.
Based on SEC 10-K filings.
$329,000 in FY2025.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 113This company $329.0K Sector average $1.1B
▼
-100.0% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $329.0K | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026